Company: GHRS
Filing Date: 2025-02-27
Form Type: 20-F
Source: 0001140361-25-006175
Chunk: 74

Company: GH Research PLC
Filing Date: 2025-02-27
Form: 20-F
Item: Item 5
Chunk 74
---
 losses since inception, including net losses of $39.0 million, $35.6 million and $22.5 million for the years ended December 31, 2024, 2023 and 2022 respectively. As of December 31, 2024, we had an accumulated deficit of $106.4 million, compared to an accumulated deficit as of December 31, 2023, of $67.9 million. We expect to incur significant expenses and operating losses for the foreseeable future as we expand our research and development activities. In addition, our losses from operations may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials, our expenditures on other research and development activities and based on foreign currency translation differences. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:

•   continue to develop and conduct clinical trials, including in expanded geographies such as the United States, for our GH001 and GH002 product candidates for our initial indications and any additional indications;
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

•   continue both the technical development and expansion of our external manufacturing capabilities for our current product candidates GH001 and GH002 and of the medical devices required to deliver these product candidates, such as
                                                                                             our proprietary aerosol delivery device for GH001;                                                                                         
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

•   initiate and continue research and development, including technical, nonclinical, clinical, and discovery efforts for any future product candidates;
--------------------------------------------------------------------------------------------------------------------------------------------------------

•   seek to identify additional product candidates;
---------------------------------------------------

•   seek regulatory approvals for our product candidates GH001 and GH002 including the medical devices required to deliver these product candidates, such as our proprietary aerosol delivery device for GH001, or any other product
                                                                                      candidates that successfully complete clinical development;                                                                                   
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

•   progress any nonclinical programs and any other work that may be required to lift the clinical hold on the study we proposed in our IND for GH001;
------------------------------------------------------------------------------------------------------------------------------------------------------

•   add operational, financial and management information systems and personnel, including personnel to support our product candidate and device development and help us comply with our obligations as a public company;
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

•   hire and retain additional personnel, such as clinical, quality control, scientific, commercial, sales, marketing and administrative personnel;
---------------------------------------------------------------------------------------------------------------------------------------------------

•   continue to prepare, file, prosecute, maintain, protect and enforce our intellectual property rights and claims;
--------------------------------------------------------------------------------------------------------------------

•   establish sales, marketing, distribution, manufacturing, supply